Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Non-Current Deferred Tax Liability (2024 - 2025)

PharmaCyte Biotech (PMCB) has disclosed Non-Current Deferred Tax Liability for 1 consecutive years, with $1.0 million as the latest value for Q2 2024.

  • On a quarterly basis, Non-Current Deferred Tax Liability changed N/A to $1.0 million in Q2 2024 year-over-year; TTM through Apr 2024 was $1.0 million, a N/A change, with the full-year FY2024 number at $1.0 million, changed N/A from a year prior.
  • Non-Current Deferred Tax Liability was $1.0 million for Q2 2024 at PharmaCyte Biotech.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.0 million in Q2 2024 to a low of $1.0 million in Q2 2024.